Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Seuk Keun | - |
dc.contributor.author | Kim, Chan Wha | - |
dc.contributor.author | Kim, Jong-Tak | - |
dc.contributor.author | Seomun, Young | - |
dc.contributor.author | Park, Min Soo | - |
dc.contributor.author | Kim, Choon Ok | - |
dc.date.accessioned | 2021-09-02T06:42:06Z | - |
dc.date.available | 2021-09-02T06:42:06Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 1173-2563 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/73233 | - |
dc.description.abstract | Background and Objective Batroxobin, a snake venom thrombin-like enzyme, converts fibrinogen into fibrin by cleaving fibrinopeptide A. It is used for hemostasis; however, the supply of native batroxobin is limited. Therefore, we developed a recombinant batroxobin (r-batroxobin) from Pichia pastoris and evaluated its pharmacodynamics and safety in humans. Methods A randomized, double-blind, placebo-controlled, single ascending-dose study was performed. Eight healthy subjects were enrolled in each r-batroxobin dose group (2.5, 5.0, or 10.0 BU/2.0mL administered intravenously), and randomized to receive r-batroxobin (n=6) or matching placebo (n=2). Safety was evaluated during the study, and pharmacodynamics was assessed using prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and fibrinogen level. Results All subjects in each cohort completed the study. No significant changes in PT or aPTT occurred after intravenous r-batroxobin administration. Compared with the placebo group, the fibrinogen level in all r-batroxobin dose groups decreased significantly to 8.68-33.57% from the baseline within 12h (p <= 0.05). The TT in the 5.0 and 10.0 BU/2.0mL groups significantly increased to 7.53-18.48% from baseline within 12h compared with that of the placebo group (p <= 0.05), whereas that of the 2.5 BU/2.0mL group exhibited non-significant changes compared with the placebo group. No serious adverse events occurred. Conclusions A single intravenous injection of r-batroxobin within a dose range of 2.5-10.0 BU/2.0mL was well tolerated and resulted in a significant decrease in fibrinogen and prolongation of TT. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ADIS INT LTD | - |
dc.subject | MASSIVE TRANSFUSION | - |
dc.subject | THROMBIN | - |
dc.subject | VENOM | - |
dc.subject | MANAGEMENT | - |
dc.subject | SURGERY | - |
dc.title | Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Chan Wha | - |
dc.identifier.doi | 10.1007/s40261-018-0673-x | - |
dc.identifier.scopusid | 2-s2.0-85049584323 | - |
dc.identifier.wosid | 000445237500004 | - |
dc.identifier.bibliographicCitation | CLINICAL DRUG INVESTIGATION, v.38, no.9, pp.829 - 835 | - |
dc.relation.isPartOf | CLINICAL DRUG INVESTIGATION | - |
dc.citation.title | CLINICAL DRUG INVESTIGATION | - |
dc.citation.volume | 38 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 829 | - |
dc.citation.endPage | 835 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MASSIVE TRANSFUSION | - |
dc.subject.keywordPlus | THROMBIN | - |
dc.subject.keywordPlus | VENOM | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SURGERY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.